Barclays Cuts GoodRx (NASDAQ:GDRX) Price Target to $6.00

GoodRx (NASDAQ:GDRX) had its price target reduced by Barclays from $10.00 to $6.00 in a report issued on Monday,Benzinga reports. They currently have an overweight rating on the stock.

A number of other research firms also recently weighed in on GDRX. Raymond James upgraded shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target for the company in a research report on Friday, August 9th. Citigroup dropped their price target on shares of GoodRx from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price target on shares of GoodRx in a research report on Friday, August 16th. Finally, UBS Group lowered their price objective on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a research report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $8.86.

GoodRx Stock Down 0.9 %

NASDAQ GDRX opened at $4.66 on Monday. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx has a 1-year low of $4.55 and a 1-year high of $9.26. The company has a 50 day moving average of $6.76 and a 200-day moving average of $7.48. The company has a market cap of $1.77 billion, a price-to-earnings ratio of -153.67, a PEG ratio of 3.24 and a beta of 1.39.

Insider Transactions at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total transaction of $83,921.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.17% of the company’s stock.

Institutional Trading of GoodRx

Several institutional investors have recently modified their holdings of the business. Rubric Capital Management LP grew its stake in shares of GoodRx by 25.2% in the third quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock worth $32,479,000 after purchasing an additional 943,226 shares during the last quarter. Dynamic Technology Lab Private Ltd grew its stake in shares of GoodRx by 260.7% in the third quarter. Dynamic Technology Lab Private Ltd now owns 44,419 shares of the company’s stock worth $308,000 after purchasing an additional 32,104 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of GoodRx by 5.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company’s stock worth $3,332,000 after purchasing an additional 26,262 shares during the last quarter. Quest Partners LLC bought a new stake in GoodRx during the third quarter valued at $160,000. Finally, CWA Asset Management Group LLC bought a new stake in GoodRx during the third quarter valued at $370,000. Institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.